[34] Wallqvist A, Fang X, Tewari SG, Ye P, Reifman J. Metabolic host responses to malarial
infection during the intraerythrocytic developmental cycle. BMC Systems Biology.
2016; 10 :58. DOI: 10.1186/s12918-016-0291-2
[35] Vangapandu S, Jain M, Kaur K, Patil P, Patel SR, Jain R. Recent advances in antimalarial
drug development. Medicinal Research Reviews. 2007; 27 (1):65–107.
[36] Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Tracking
Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in
plasmodium falciparum malaria. The New England Journal of Medicine. 2014; 371 :411–
- DOI: 10.1056/NEJMoa1314981
[37] Njokah MJ, Kang’ethe JN, Kinyua J, Kariuki D, Kimani FT. In vitro selection ofPlasmo-
dium falciparumPfcrt and Pfmdr1 variants by artemisinin. Malaria Journal. 2016; 15
(1):381. DOI: 10.1186/s12936-016-1443-y
[38] Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, et al.
Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to
artemisinin-based combination therapies. Nature Communications. 2016; 7 :11553.
[39] Cohen J, Benns S, Vekemans J, Leach A, Schnermann L. Development of the RTS, S/AS
vaccine candidate from concept to phase III. In: Mehlhorn H, editor. Progress in Parasi-
tology. Parasitology Research Monographs: Springer; 2011. Vol. 2, pp. 121–133.
[40] WHO. Background paper: malaria vaccine RTS, S/AS01 [Internet]. 2015. Available from:
http://www.who.int/immunization/sage/meetings/2015/october/1_Final_malaria_vacci-
ne_background_paper_v2015_09_30.pdf [Accessed: 2016-09-15]
[41] Long CA, Zavala F. Malaria vaccines and human immune responses. Current Opinion
in Microbiology. 2016; 32 :96–102. DOI: 10.1016/j.mib.2016.04.006
[42] Schmidt TJ, Khalid SA, Romanha AJ, Alves TMA, Biavatti MW, Brun R, Da Costa FB,
et al. The potential of secondary metabolites from plants as drugs or leads against
protozoan neglected diseases—part I. Current Medicinal Chemistry. 2012; 19 :2128–2175.
[43] Schmidt TJ, Khalid SA, Romanha AJ, Alves TMA, Biavatti MW, Brun R, et al. The
potential of secondary metabolites from plants as drugs or leads against protozoan
neglected diseases—part II. Current Medicinal Chemistry. 2012; 19 :2176–2228.
[44] Noster S, Kraus LJ. In vitro antimalarial activity of Coutarea latiflora and Exostema
caribaeum extracts on Plasmodium falciparum. Planta Medica. 1990;56(1):63–65.
[45] Köhler I, Jenett-Siems K, Mockenhaupt FP, Siems K, Jakupovic J, González JC, Hernández
MA, et al. In vitro antiplasmodial activity of 4-phenylcoumarins from Exostema mexica-
num. Planta Medica. 2001; 67 (1):89–91.
[46] Argotte-Ramos R, Ramírez-Avila G, Rodríguez-Gutiérrez MC, Ovilla-Muñoz M,
Lanz-Mendoza H, Rodríguez MH, Gonzalez-Cortazar M, et al. Antimalarial 4-
phenylcoumarins from the stem bark of Hintonia latiflora. Journal of Natural Products.
2006; 69 (10):1442–1444.
Mexican Medicinal Plants as an Alternative for the Development of New Compounds Against Protozoan Parasites
http://dx.doi.org/10.5772/6725985